I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

I am a healthcare professional
(outside the UK and Australia):

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Jun 15 / Springer Healthcare

2020 Annual Meeting In-Depth Report: Lung Cancer

Description

This in-depth report of the American Society of Clinical Oncology Annual Meeting 2020 outlines and discusses recent research in lung cancer.

American Society of Clinical Oncology 2020 ASCO Annual Meeting

May 29–31st, 2020

In-Depth Report: Lung Cancer

 

The Annual Meeting of the American Society of Clinical Oncology (ASCO), now in its 56th year, took place under a new virtual format on 29–31 May 2020. Opening the meeting, ASCO President Howard A. “Skip” Burris III highlighted that although COVID-19 had changed the format of this year’s ASCO 2020, the collective determination to make progress against cancer was as strong as ever.


ASCO President Howard A. “Skip” Burris III

Dr Burris explained that the COVID-19 pandemic has changed the way patients with cancer receive care and has encouraged healthcare professionals in the oncology community and their patients to weigh the risks and benefits of delaying treatment.

Dr Burris highlighted that data on how COVID-19 was impacting patients was being collected through the new ASCO Registry and CancerLinQ database, which this year crossed a milestone of 2.5 million patients.

As ever, this year’s ASCO meeting aimed to enable clinicians to understand how and when to integrate novel research into patient care. Dr Burris noted that the galvanising theme of the ASCO20 Virtual Scientific Program – “Unite and Conquer: Accelerating Progress Together” – would take on even more resonance given the extraordinary times as ASCO’s global audience learnt about new developments in cancer care.

“The world is grappling with a pandemic and we are all readjusting to a new reality, but it cannot stop us. We, the ASCO Community, are absolutely unwilling to let anything stop us in the fight against cancer.”

Howard A. “Skip” Burris III, ASCO President

Lung Cancer

Lung Cancer, NSCLC, Small Cell, Other

Interim DFS data from the Phase III ADAURA study presented by Roy S. Herbst, Yale School of Medicine and Yale Cancer Center, New Haven, USA, unequivocally support the use of osimertinib, a third-generation, CNS-active, EGFR-tyrosine kinase inhibitor, as a standard component of care in patients with early-stage EGFR-mutated non-small-cell lung cancer (NSCLC) following complete tumour resection (Abstract LBA5; NCT02511106). ADAURA included patients with:

Patient populations in the ADAURA study

This unplanned interim analysis revealed a significant 83% reduction in the risk of disease recurrence or death with the use of adjuvant osimertinib in comparison with placebo among patients with stage II or IIIA non-squamous NSCLC, which met and exceeded expectations for this global study. At the time of ADAURA being unblinded, the disease-free survival (DFS) data for the overall population were only 29% mature; however, the 2 year DFS rate was 89% with osimertinib versus 53% with placebo. Notably, the strong DFS advantage observed with osimertinib persisted across all patient subgroups, including those patients who received adjuvant chemotherapy and those who did not. Overall survival (OS) data are not yet mature.

“Adjuvant osimertinib provides an effective new treatment strategy for patients with stage IB/II/IIIA EGFR-mutated NSCLC following complete tumour resection and adjuvant chemotherapy.”

Roy S. Herbst, Yale School of Medicine and Yale Cancer Center, New Haven, USA

David R. Spigel, Sarah Cannon Research Institute, Nashville, USA, emphasised the strengths of the ADAURA study but questioned whether osimertinib was eliminating disease or simply controlling and deferring disease that could not be eradicated. However, despite the questions that remain regarding survival and limited study follow-up, Dr Spigel felt that he would still choose to use osimertinib.

“I believe all patients with NSCLC - at any stage - should now be tested for the presence of a sensitising EGFR mutation.”

David R. Spigel, Sarah Cannon Research Institute, Nashville, USA

Data from the Phase II PrE0505 study suggest patients with treatment-naïve and unresectable malignant pleural mesothelioma may respond to treatment with durvalumab when used in combination with pemetrexed and cisplatin according to Patrick M. Forde, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, USA (Abstract 9003; NCT02899195). Patients received a maximum of six cycles of durvalumab plus chemotherapy, followed by one year of maintenance durvalumab alone. The 6-, 12- and 24-month OS rates were 87.2%, 70.4% and 44.2%, respectively, while corresponding progression-free survival (PFS) rates were 69.1%, 16.4% and 10.9%. Median PFS was 6.7 months. These findings will be explored further in the forthcoming Phase III DREAM3R (PrE0506) study.

PrE0505 study: median OS

Median PFS in the PrE0505 study

“OS and PFS did not correlate with various tumour characteristics, including TMB and PD-L1 expression.”

Patrick M. Forde, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, USA

 

Lung Cancer

Metastatic NSCLC


12-month OS in the CheckMate 9LA study

Data on first-line immunotherapy strategies for metastatic NSCLC included those from the Phase III CheckMate 227 (Abstract 9500; NCT02477826) and CheckMate 9LA (Abstract 9501; NCT03215706) studies. Three-year follow-up data from CheckMate 227 demonstrated that the combination of nivolumab and ipilimumab as first-line therapy continued to provide durable and long-term OS benefits compared with platinum-doublet chemotherapy in patients with advanced NSCLC and programmed cell death ligand 1 (PD-L1) ≥1% according to Suresh S. Ramalingam, Winship Cancer Institute, Atlanta, USA.

Martin Reck, German Center for Lung Research, Großhansdorf, Germany, presented data from the CheckMate 9LA study supporting the use of nivolumab plus ipilimumab alongside first-line, histology-driven chemotherapy in patients with advanced NSCLC without sensitising EGFR or ALK mutations. Nivolumab in combination with NSCLC-optimised ipilimumab and a limited course of chemotherapy resulted in a statistically significant improvement in OS compared with four cycles of chemotherapy as first-line treatment. One-year OS rates were 63% versus 47%, respectively, and this clinical benefit was consistent across all efficacy measures in key subgroups including by PD-L1 and histology. Median OS was
15.6 months with nivolumab plus ipilimumab and chemotherapy versus 10.9 months for chemotherapy alone. Of note, the combination regimen appeared to be efficacious in patients with CNS metastases.

“Nivolumab and ipilimumab, together with a limited course of chemotherapy, should be considered as a new first-line treatment opportunity for patients with NSCLC.”

Martin Reck, German Center for Lung Research, Großhansdorf, Germany

Trastuzumab deruxtecan (T-Dxd) is a novel antibody-drug conjugate composed of an anti-HER2 antibody, cleavable tetrapeptide-based linker, and topoisomerase I inhibitor payload. Interim data from the ongoing Phase II DESTINY-Lung01 study demonstrated a high overall response rate and durable responses with the use of T-Dxd in patients with HER2-mutated NSCLC, said Egbert F. Smit, Netherlands Cancer Institute, Amsterdam, Netherlands (Abstract 9504; NCT03505710). The safety profile of T-Dxd was reported to be consistent with that in previously reported studies, with drug-related interstitial lung disease noted in some patients.

“These data demonstrate the potential of trastuzumab deruxtecan as a new treatment option for patients with HER2-mutated NSCLC.”

Egbert F. Smit, Netherlands Cancer Institute, Amsterdam, Netherlands

Closing Remarks

In response to the COVID-19 pandemic, ASCO completely reimagined and reinvented its 2020 Annual Meeting by delivering a successful virtual meeting. This virtual platform still had the aim of achieving an engaging and educational meeting experience for participants from around the world. Delegates were able to view data, clinical experiences, patient perspectives and best practices that will hopefully stimulate new ways of thinking and ultimately translate into optimal patient care within the oncology field.

 

©Springer Healthcare 2020. This content has been independently selected and developed by Springer Healthcare and licensed by Roche for Medically. The topics covered are based on therapeutic areas specified by Roche. Inclusion or exclusion of any product does not imply its use is either advocated or rejected. Use of trade names is for product identification only and does not imply endorsement. Opinions expressed do not reflect the views of Springer Healthcare. Springer Healthcare assumes no responsibility for any injury or damage to persons or property arising out of, or related to, any use of the material or to any errors or omissions. Please consult the latest prescribing information from the manufacturer for any products mentioned in this material.